Antigen Capture and Immune Modulation by Bacterial Outer Membrane Vesicles as In Situ Vaccine for Cancer Immunotherapy Post‐Photothermal Therapy. Issue 14 (12th February 2022)

• Record Type: Journal Article
• Authors: Li, Yao; Zhang, Kaiyue; Wu, Yao; Yue, Yale; Cheng, Keman; Feng, Qingqing; Ma, Xiaotu; Liang, Jie; Ma, Nana; Liu, Guangna; Nie, Guangjun; Ren, Lei; Zhao, Xiao
• Is Part Of: Small. Volume 18:Issue 14(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-02-12
• Subjects: indoleamine 2, 3‐dioxygenase -- antigen capture -- in situ vaccines -- photothermal therapies; Nanotechnology -- Periodicals; Nanoparticles -- Periodicals; Microtechnology -- Periodicals; 620.5
• DOI: 10.1002/smll.202107461
• Languages: English
• ISSNs: 1613-6810

Abstract

Abstract: Tumor antigens released from tumor cells after local photothermal therapy (PTT) can activate the tumor‐specific immune responses, which are critical for eliminating the residual lesions and distant metastases. However, the limited recognition efficiency of released tumor antigens by the immune system and the immunosuppressive microenvironment lead to ineffective antitumor immunity. Here, an in situ multifunctional vaccine based on bacterial outer membrane vesicles (OMVs, 1‐MT@OMV‐Mal) is developed by surface conjunction of maleimide groups (Mal) and interior loading with inhibitor of indoleamine 2, 3‐dioxygenase (IDO), 1‐methyl‐tryptophan (1‐MT). 1‐MT@OMV‐Mal can bind to the released tumor antigens after PTT, and be efficiently recognized and taken up by dendritic cells. Furthermore, in situ injection of 1‐MT@OMV‐Mal simultaneously overcomes the immune inhibition of IDO on tumor‐infiltrating effector T cells, leading to remarkable inhibition on both primary and distant tumors. Together, a promising in situ vaccine based on OMVs to facilitate immune‐mediated tumor clearance after PTT through orchestrating antigen capture and immune modulation is presented. Abstract : An in situ multifunctional vaccine based on bacterial outer membrane vesicles (OMVs, 1‐MT@OMV‐Mal) via surface conjunction of maleimide groups (Mal) and interior loading with inhibitor of indoleamine 2, 3‐dioxygenase, 1‐methyl‐tryptophan (1‐MT) is presented. By the strategy of orchestrating antigen capture and immune modulation, the in situ vaccine leads to the remarkable inhibition on both primary and distant tumors.